These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 17405216)
21. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302 [TBL] [Abstract][Full Text] [Related]
22. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks. Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697 [No Abstract] [Full Text] [Related]
23. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734 [TBL] [Abstract][Full Text] [Related]
24. The importance of sequencing in treatment options. Berger DS Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121 [No Abstract] [Full Text] [Related]
25. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives. Horne R; Cooper V; Fisher M AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512 [TBL] [Abstract][Full Text] [Related]
27. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability. Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919 [TBL] [Abstract][Full Text] [Related]
28. [Entry inhibitors. Ring-free for a new principle of action]. Rümmelein N; Jäger H MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578 [TBL] [Abstract][Full Text] [Related]
29. Use of darunavir and enfuvirtide in a pregnant woman. Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223 [TBL] [Abstract][Full Text] [Related]
30. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478 [No Abstract] [Full Text] [Related]
31. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A; Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. True AL; Chiu YY; Demasi RA; Stout R; Patel I Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431 [TBL] [Abstract][Full Text] [Related]
33. Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002. Glutzer E AIDS Read; 2003 Mar; 13(3 Suppl):S14-6. PubMed ID: 12765161 [TBL] [Abstract][Full Text] [Related]
34. Enfuvirtide (Fuzeon) for HIV Infection. Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195 [No Abstract] [Full Text] [Related]
36. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients. Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088 [TBL] [Abstract][Full Text] [Related]
37. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient. Oates E; Dzintars K Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170 [TBL] [Abstract][Full Text] [Related]
38. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study). Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881 [TBL] [Abstract][Full Text] [Related]
39. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306 [TBL] [Abstract][Full Text] [Related]
40. Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature. Sidhu HK; Chaffee BH; Tvetenstrand CD; Sidhu JS Int J Surg Pathol; 2010 Oct; 18(5):384-7. PubMed ID: 19223380 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]